Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Overview
This bill reauthorizes a program focused on preventing and treating sickle cell disease and its complications. It aims to expand research efforts into the causes and potential cures for heritable blood disorders, including sickle cell disease. The bill increases funding for the demonstration program to support these initiatives. Congress expresses a desire for continued research into these conditions.
Key provisions
- Reauthorizes a demonstration program for sickle cell disease prevention and treatment.
- Expands the program’s focus to include the prevention and treatment of complications of sickle cell disease.
- Modifies grant-making language to require making grants instead of entering into contracts.
- Increases funding for the program from $4,455,000 to $8,205,000 per year for the period 2025-2029.
- Encourages further research into the causes and cures of heritable blood disorders.
Who is affected
- Individuals with sickle cell disease
- Families affected by sickle cell disease
- Researchers studying sickle cell disease and related blood disorders
- Public health agencies
Notable changes
- Increases funding for the sickle cell disease demonstration program.
- Broadens the program’s scope to include treatment of complications.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
4 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours